<p>Immunome（納斯達克：IMNM - 獲取免費報告）預計將在 2025 年第二季度的收益結果於 8 月 11 日星期一市場開盤前公佈。分析師預計該公司將公佈每股收益（$0.52）和季度收入為 103 萬美元。</p>
<ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
<p>Immunome（納斯達克：IMNM - 獲取免費報告）上一次公佈收益結果是在 5 月 12 日星期一。該公司報告季度每股收益為（$0.52），超出市場共識預期的（$0.66）$0.14。Immunome 的淨利潤率為負的 1,875.21%，股本回報率為負的 71.65%。該公司在本季度的收入為 293 萬美元，而分析師的預期為 46 萬美元。分析師平均預計 Immunome 在當前財年的每股收益為-$2，在下一個財年的每股收益為-$3。</p>
<h2>Immunome 價格表現</h2>
<p>IMNM 的股票在星期一開盤價為$10.48。Immunome 的年低為$5.15，年高為$16.73。該公司的 50 日移動平均線為$9.38，200 日移動平均線為$8.89。該股票的市值為 9.1145 億美元，市盈率為-3.29，貝塔值為 1.92。</p>
<h2>分析師設定新目標價</h2>
<p>幾位分析師最近對該股票發表了評論。華爾街 Zen 在 5 月 22 日星期四的報告中將 Immunome 的股票評級從 “賣出” 上調至 “持有”。Wedbush 在 5 月 13 日星期二的研究報告中重申了 “跑贏大盤” 的評級，並將 Immunome 的目標價定為$21.00（從$33.00 下調）。一位分析師對該股票給予了持有評級，六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為$23.33。</p>
<p><strong>查看我們對 Immunome 的最新分析</strong></p>
<h2>內部人士買賣</h2>
<p>在相關消息中，董事 Jean Jacques Bienaime 在 6 月 3 日星期二的交易中購買了 5,000 股該公司的股票。該股票的平均購買成本為每股$9.38，總交易額為$46,900.00。購買後，該董事直接持有該公司 36,415 股股票，價值$341,572.70。這筆交易代表了他們持股比例的 15.92% 的增長。該購買在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。當前 8.60% 的股票由內部人士持有。</p>
<h2>對 Immunome 的對沖基金看法</h2>
<p>一位機構投資者最近增加了對 Immunome 股票的持倉。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Immunome, Inc.（納斯達克：IMNM - 免費報告）的持股增加了 44.4%，根據其最近向證券交易委員會（SEC）的備案。該公司在本季度購買了額外的 14,398 股後，持有該公司 46,821 股股票。根據其最近的 SEC 備案，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.持有 Immunome 的股份佔 0.05%，價值$316,000。機構投資者持有該公司 44.58% 的股票。</p>
<h2>Immunome 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immunome, Inc.是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在進行的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期臨牀試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體治療；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票比 Immunome 更好</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>在美聯儲今年秋季降息之前考慮這隻銀行 ETF</li>
<li>特殊目的收購公司（SPAC）你需要知道的事情</li>
<li>為什麼這三隻市場超越者正在支持他們的回購計劃</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>每個價值投資者現在應該關注的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Immunome 嗎？</h2>
<p>在考慮 Immunome 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Immunome 並不在名單上。</p>
<p>雖然 Immunome 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMNM

<p>Immunome（納斯達克代碼：IMNM）將於 8 月 11 日發佈 2025 年第二季度財報，分析師預計每股虧損為 0.52 美元，收入為 103 萬美元。該公司此前報告的每股虧損為 0.52 美元，超出預期。Immunome 的股票開盤價為 10.48 美元，市值為 9.1145 億美元。分析師的評級意見不一，普遍目標價為 23.33 美元。近期內部人士購股和機構投資活動引起關注，顯示出對公司在靶向癌症治療領域增長潛力的興趣</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $1.03 million for the quarter.</p>
<div class="lb-trans"><p>Immunome（納斯達克：IMNM - 獲取免費報告）預計將在 2025 年第二季度的收益結果於 8 月 11 日星期一市場開盤前公佈。分析師預計該公司將公佈每股收益（$0.52）和季度收入為 103 萬美元。</p>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. The company had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Immunome（納斯達克：IMNM - 獲取免費報告）上一次公佈收益結果是在 5 月 12 日星期一。該公司報告季度每股收益為（$0.52），超出市場共識預期的（$0.66）$0.14。Immunome 的淨利潤率為負的 1,875.21%，股本回報率為負的 71.65%。該公司在本季度的收入為 293 萬美元，而分析師的預期為 46 萬美元。分析師平均預計 Immunome 在當前財年的每股收益為-$2，在下一個財年的每股收益為-$3。</p>
</div><h2>Immunome Price Performance</h2>
<div class="lb-trans"><h2>Immunome 價格表現</h2>
</div><p>Shares of IMNM opened at $10.48 on Monday. Immunome has a one year low of $5.15 and a one year high of $16.73. The company has a 50-day moving average of $9.38 and a two-hundred day moving average of $8.89. The stock has a market cap of $911.45 million, a price-to-earnings ratio of -3.29 and a beta of 1.92.</p>
<div class="lb-trans"><p>IMNM 的股票在星期一開盤價為$10.48。Immunome 的年低為$5.15，年高為$16.73。該公司的 50 日移動平均線為$9.38，200 日移動平均線為$8.89。該股票的市值為 9.1145 億美元，市盈率為-3.29，貝塔值為 1.92。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Immunome from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, May 22nd. Wedbush reiterated an &#34;outperform&#34; rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $23.33.</p>
<div class="lb-trans"><p>幾位分析師最近對該股票發表了評論。華爾街 Zen 在 5 月 22 日星期四的報告中將 Immunome 的股票評級從 “賣出” 上調至 “持有”。Wedbush 在 5 月 13 日星期二的研究報告中重申了 “跑贏大盤” 的評級，並將 Immunome 的目標價定為$21.00（從$33.00 下調）。一位分析師對該股票給予了持有評級，六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為$23.33。</p>
</div><p><strong>Check Out Our Latest Analysis on Immunome</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Immunome 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In related news, Director Jean Jacques Bienaime bought 5,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average cost of $9.38 per share, for a total transaction of $46,900.00. Following the purchase, the director directly owned 36,415 shares in the company, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. 8.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Jean Jacques Bienaime 在 6 月 3 日星期二的交易中購買了 5,000 股該公司的股票。該股票的平均購買成本為每股$9.38，總交易額為$46,900.00。購買後，該董事直接持有該公司 36,415 股股票，價值$341,572.70。這筆交易代表了他們持股比例的 15.92% 的增長。該購買在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。當前 8.60% 的股票由內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Immunome</h2>
<div class="lb-trans"><h2>對 Immunome 的對沖基金看法</h2>
</div><p>An institutional investor recently raised its position in Immunome stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 44.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,821 shares of the company's stock after buying an additional 14,398 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Immunome worth $316,000 as of its most recent SEC filing. Institutional investors own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>一位機構投資者最近增加了對 Immunome 股票的持倉。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Immunome, Inc.（納斯達克：IMNM - 免費報告）的持股增加了 44.4%，根據其最近向證券交易委員會（SEC）的備案。該公司在本季度購買了額外的 14,398 股後，持有該公司 46,821 股股票。根據其最近的 SEC 備案，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.持有 Immunome 的股份佔 0.05%，價值$316,000。機構投資者持有該公司 44.58% 的股票。</p>
</div><h2>Immunome Company Profile</h2>
<div class="lb-trans"><h2>Immunome 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在進行的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期臨牀試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體治療；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Consider This Bank ETF Before The Fed Cuts Rate This Fall</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Why These 3 Market-Beaters Are Backing Up Their Buyback Trucks</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>3 Stocks Every Value Investor Should Watch Out for Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Immunome 更好</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>在美聯儲今年秋季降息之前考慮這隻銀行 ETF</li>
<li>特殊目的收購公司（SPAC）你需要知道的事情</li>
<li>為什麼這三隻市場超越者正在支持他們的回購計劃</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>每個價值投資者現在應該關注的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Immunome 嗎？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Immunome 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Immunome 並不在名單上。</p>
</div><p>While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunome 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immunome (IMNM) 將在週一公佈季度財報